Navigation Links
Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
Date:7/22/2009

pipeline through partnerships or licensing agreements, while focusing our R&D efforts on advancing our later-stage clinical programs highlighted by our bavituximab Phase II cancer program, which is already generating promising clinical data."

Commenting on the licensing agreement, Dr. Achim Kaufhold, chief executive officer of Affitech, said, "Using advanced phage display technologies, Affitech successfully identified fully human, potent and selective anti-VEGF antibodies as part of a previous research and development collaboration with Peregrine. As a result of the recently completed reverse acquisition of Pharmexa, Affitech has now added product development expertise to its drug discovery capabilities. We are therefore delighted now to have acquired the exclusive worldwide development and commercialization rights for this exciting program."

Anti-VEGF therapy has become a standard part of treatments for many different types of solid tumors. According to projections of some market analysts, sales of anti-VEGF antibodies are expected to exceed $10 billion by 2015. The fully human and selective anti-VEGF monoclonal antibody, r84, which is the most advanced candidate in Peregrine's anti-VEGF antibody program, targets the cancer-promoting growth factor VEGF. Data presented at IBC's 5th Annual International Anti-Angiogenesis Conference in 2007 showed that r84 was as effective as Avastin(R) (bevacizumab) in inhibiting tumor growth in a number of models of human cancers, including a mouse model of human breast cancer. r84 is distinctive because it selectively blocks VEGF from binding to VEGF receptor 2 (VEGFR2), while non-selective agents such as Avastin block binding to both VEGFR2 and VEGF receptor 1 (VEGFR1). Selective anti-VEGF agents such as r84 may have safety and efficacy advantages over non-selective approaches. In addition, the fully human nature of the r84 antibody minimizes the risk of an immune response ag
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.; Affitech A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... USA (PRWEB) November 19, 2014 The ... our lives was shared with more than 200 primary ... postgraduate students from the University of Otago Physics Department ... . The Otago students, members of the university’s OSA/SPIE ... Zealand in early September, giving children from small, rural ...
(Date:11/21/2014)... The report, "Synthetic Biology Market by ... Technology (Bioinformatics, Nanotechnology, Gene Synthesis, Cloning & ... Global Forecast to 2018", analyses and studies ... challenges. , Browse 99 market data tables ... and in-depth TOC of the global synthetic ...
(Date:11/21/2014)... November 21, 2014 2014 Deep ... Industry” is a professional and in-depth research report ... ferrocyanide information, like its definition, classification, application, ... overview. This report covers the international market analysis, ... (such as the US, Europe, Asia, China, Japan ...
(Date:11/21/2014)... and SAN DIEGO , Nov. 20, ... announced that President and CEO Marc Hedrick , M.D. will ... DATE:   Thursday, December 4, 2014 TIME:    11:15 ... here or paste this URL into your browser,s address ... investors pre-register to save time and receive event updates. ...
Breaking Biology Technology:Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4
... Pa., May 7 Encorium Group, Inc. ... multinational contract research organization (CRO) that provides design, ... patient registries to many of the world,s leading ... M.D., Ph.D. has been appointed Head Consultant of ...
... EAST BRUNSWICK, N.J., May 7 Savient Pharmaceuticals, Inc. ... biologics license application (BLA) for KRYSTEXXA (TM) (pegloticase), ... patients, will be reviewed by the Arthritis Advisory Committee ... on June 16, 2009. In December, the FDA ...
... May 7 Sigma-Aldrich Corporation (Nasdaq: SIAL ) ... Lynch 2009 Healthcare Conference on Wednesday, May 13th at 2:00 ... parties may listen via live audio broadcast over the Internet ... can click the "Webcast" icon to access this file. ...
Cached Biology Technology:Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team 2Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team 3Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team 4Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout 2Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout 3Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout 4Sigma-Aldrich to Present at the Bank of America and Merrill Lynch 2009 Healthcare Conference on Wednesday, May 13, 2009 2
(Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
(Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)...  The Secure Identity & Biometrics Association (SIBA) ... the formation of The Airport Entry and Exit ... and Biometric Entry and Exit Solutions Framework for ... from BORDERPOL, the international non-profit organization that works ... regarding border security, traveler and migration systems. ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... CHESTERFIELD, Mo. , April 22, 2013 The ... panel of experts from multiple disciplines, including farmers, media, ... questions surrounding GMOs. This discussion was moderated by CNBC ... The Food Dialogues℠: Chicago , which ...
... checked were for native Australian millipede species and were published ... and the Atlas of Living Australia , ALA. GBIF ... but disclaim any responsibility for errors in museum databases, instead ... fit for purpose. The auditing was done voluntarily by ...
... April 2013. Researchers have known for some years that the ... Arctic when the waters in its traditional habitat become too ... are now moving up as far as Spitsbergen into the ... two and a half years, biologists from the Alfred Wegener ...
Cached Biology News:CNBC Senior Analyst Ron Insana Moderates Discussion On Biotech Seeds At The Food Dialogues(SM): Chicago 2CNBC Senior Analyst Ron Insana Moderates Discussion On Biotech Seeds At The Food Dialogues(SM): Chicago 3Online biodiversity databases audited: 'Improvement needed' 2Atlantic cod in for even more stress? 2Atlantic cod in for even more stress? 3
Component of HyperMu™ Insertion Kit...
...
Request Info...
... Rabbits x 2 , ... bleed x1 /each , Immunizations/Boost injections ... (app. 5 ml) x1 /each , ... /each , Final Bleed ~ 100 ml blood ...
Biology Products: